CV Share Price Performance
US$4.83
1.33 (38.00%)
54.0% undervalued intrinsic discount
US$10.50
Fair Value
Price US$4.83
AnalystConsensusTarget US$10.50
AnalystHighTarget US$14.00
AnalystLowTarget US$7.00
Fair ValueUS$10.50
Share Pricen/a
CapsoVision, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
CV Community Narratives
AN
Fair Value US$10.5 54.0% undervalued intrinsic discount
Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI Player
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$14 65.5% undervalued intrinsic discount
AI Capsule Endoscopy And Pancreatic Screening Will Transform Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$7 31.0% undervalued intrinsic discount
AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy Adoption
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy Adoption
Catalysts About CapsoVision CapsoVision develops wire free, cloud connected capsule endoscopy systems for gastrointestinal disease screening and diagnosis. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$7
31.0% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
81.99% p.a.
Profit Margin
11.76%
Future PE
54.02x
Price in 2029
US$4.87
Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI Player
Catalysts About CapsoVision CapsoVision develops cloud connected capsule endoscopy systems that use panoramic imaging and AI to support noninvasive gastrointestinal screening and diagnostics. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$10.5
54.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
74.32% p.a.
Profit Margin
5.84%
Future PE
185.77x
Price in 2029
US$7.31
AI Capsule Endoscopy And Pancreatic Screening Will Transform Long Term Prospects
Catalysts About CapsoVision CapsoVision develops noninvasive, AI-enabled capsule endoscopy systems for gastrointestinal screening and diagnostics using panoramic imaging and a cloud-based workflow. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$14
65.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
80.45% p.a.
Profit Margin
11.7%
Future PE
111.48x
Price in 2029
US$9.75
Trending Discussion
Recently Updated Narratives
AN
AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy Adoption
Fair Value: US$7 31.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI Player
Fair Value: US$10.5 54.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI Capsule Endoscopy And Pancreatic Screening Will Transform Long Term Prospects
Fair Value: US$14 65.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
CapsoVision, Inc. Key Details
About CV
- Founded
- 2005
- Employees
- 90
- CEO
- WebsiteView website
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. It offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). The company also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoAccess, a Capsule data access system; CapsoView, a data access reading device for viewing capsule videos; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. It serves gastrointestinal medical practices, clinics, and hospitals. The company sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Recent CV News & Updates
